T CELL IMMUNITY TO POLYOMA VIRUS-INDUCED TUMORS

Project: Research project

Description

DESCRIPTION Cytotoxic T lymphocytes (CTL) play a role in host defense against neoplastic cells. Analysis of their immunoregulation and effector mechanism is limited by (a) unknown tumor- specific antigens, (b) experimental tumor models that do not reflect "naturally-occurring" neoplastic disease and (c) polyclonal CTL responses. Polyoma virus is a natural mouse pathogen capable of inducing a diverse variety of epithelial and mesenchymal cell-derived tumors which are the same cell types giving rise to the majority of human tumors. Inbred mouse strains vary in their susceptibility to polyoma tumorigenesis. Resistance to polyoma tumors is mediated by T-cells, with no apparent contribution from antiviral antibody. A subset of H-2k mouse strains that carry an endogenous superantigen encoded by the Mtv-7 provirus are susceptible to polyoma tumorigenicity. Polyoma-specific CD8+ CTL in the resistant H-2k Mtv-7- mice appear to express Vb6-T-cell receptor (TCR), which are deleted in H-2k Mtv-7+ mice. The principal investigator will test the hypothesis that immunity to polyoma tumors is dominated by an oligoclonal CD8+Vb6+ CTL response directed to a single viral epitope. Aim 1 is to determine whether polyoma-specific CD8+Vb6+ CTL protect H-2k mice from polyoma tumors. The investigators have isolated anti-polyoma CTL clones from resistant H-2k mice and found them to be CD8+Vb6+. These CTL clones will enable the principal investigator to determine the antigenic diversity of polyoma tumors. The final aim is to compare TCR sequences of CD8+Vb6+ CTL lines which recognize the same viral peptide-MHC complexes to determine the extent of conservation of the other TCR domains, particularly the CDR3 regions. The availability of an oligoclonal, monospecific anti-tumor CTL response in vivo will permit detailed investigation of the induction, immunoregulation and tumoricidal mechanism(s) of this T-cell subset, and thereby facilitate development of immunotherapeutic strategies to neoplastic disease.
StatusFinished
Effective start/end date7/1/965/31/12

Funding

  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $283,860.00
  • National Institutes of Health: $110,770.00
  • National Institutes of Health: $225,372.00
  • National Institutes of Health: $304,921.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $292,613.00
  • National Institutes of Health: $280,839.00
  • National Institutes of Health: $68,850.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $58,463.00
  • National Institutes of Health: $292,613.00
  • National Institutes of Health: $283,860.00
  • National Institutes of Health: $283,860.00
  • National Institutes of Health
  • National Institutes of Health: $292,613.00
  • National Institutes of Health
  • National Institutes of Health: $292,613.00

Fingerprint

Polyomavirus
Immunity
T-Lymphocytes
Cytotoxic T-Lymphocytes
Neoplasms
Viruses
T-Cell Antigen Receptor
Antiviral Agents
Epitopes
Cytokines
Carcinogenesis
Research Personnel
Virus Diseases
Clone Cells